Skip to main content
OpenTrials

Clinical trial condition

Anemia, Refractory, with Excess of Blasts

Explore clinical trials studying Anemia, Refractory, with Excess of Blasts. Study availability and eligibility vary by location and protocol.

244 public trials 36 recruiting studies
Refine in advanced search Browse all conditions

Anemia, Refractory, with Excess of Blasts trial results

Active, Not Recruiting

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

NCT05589896

Conditions
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, +39 more
Locations
  • City of Hope Duarte, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Emory University - Winship Cancer Institute Atlanta, Georgia, United States
  • Henry Ford Cancer Institute Detroit, Michigan, United States
View Trial Details
Active, Not Recruiting

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT05600894

Conditions
Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +20 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • UC Irvine Health Cancer Center-Newport Costa Mesa, California, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UCI Health Laguna Hills Laguna Hills, California, United States
View all 34 locations
View Trial Details
Active, Not Recruiting

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976

Conditions
Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +24 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 294 locations
View Trial Details
Active, Not Recruiting

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

NCT00392353

Conditions
Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, +27 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States
  • North Shore University Hospital Manhasset, New York, United States
  • Mount Sinai Hospital New York, United States
View Trial Details
Active, Not Recruiting

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

NCT04202835

Conditions
Acute Leukemia, Anemia, Anemia, Refractory, +18 more
Locations
  • Kinghorn Cancer Centre, St Vincent's Health Network Darlinghurst, New South Wales, Australia
  • Royal North Shore Hospital St Leonards, New South Wales, Australia
  • Australasian Leukaemia and Lymphoma Group Melbourne, Victoria, Australia
  • CancerCare Manitoba Winnipeg, Manitoba, Canada
View Trial Details

Related conditions